Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin

被引:0
作者
Berini, Elvira Oliva [1 ]
Alvarez, Pilar Galan [1 ]
Onrubia, Ana Maria Pacheco [1 ]
机构
[1] Hosp Mateu Orfila, Serv Hematol & Hemoterapia, Mao 07703, Illes Balears, Spain
来源
MEDICINA CLINICA | 2008年 / 131卷 / 03期
关键词
acenocoumarol; warfarin; hemorragic risk;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: Long half life oral anticoagulants have shown a higher anticoagulation stability and a lower hemorragic risk than those of a short half life. We have compared therapeutic stability and hemorragic risk of acenocoumarol versus warfarin in 2 groups of patients on preventive anticoagulation because of atrial fibrilation (international normalised ratio [INR]: 2-3). PATIENTS AND METHOD: Data on 120 patients treated with acenocoumarol and 120 on warfarin treatment who had started and continued treatment in our hospital for a minimum of a year was collected. RESULTS: The percentage of visits within the intended range of INR (2 to 3) was 65.5% with warfarin and 63.4% with acenocoumarol. Thirty percent of patients on warfarin had 75% or more of their controls within range, while for those treated with acenocoumarol this percentage was 22.5%. In the acenocoumarol group, 0.3 visits/patient/year presented an INR >= 6 versus 0.07 in the warfarin group (p = 0.003). CONCLUSIONS: Patients treated with acenocoumarol show a higher risk of presenting with an INR >= 6, but no statistically significant differences are observed in therapeutic stability.
引用
收藏
页码:96 / 97
页数:2
相关论文
共 7 条
[1]   Warfarin or acenocoumarol: Which is better in the management of oral anticoagulants? [J].
Barcellona, D ;
Vannini, ML ;
Fenu, L ;
Balestrieri, C ;
Marongiu, F .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (06) :899-902
[2]   Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus. phenprocoumon [J].
Fihn, SD ;
Gadisseur, AAP ;
Pasterkamp, E ;
van der Meer, FJM ;
Breukink-Engbers, WGM ;
Geven-Boere, LM ;
van Meegen, E ;
de Vries-Goldschmeding, H ;
Antheunissn-Anneveld, I ;
van't Hoff, R ;
Harderman, D ;
Smink, M ;
Rosendaal, FR .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (02) :260-266
[3]   Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon [J].
Gadisseur, APA ;
van der Meer, FJM ;
Adriaansen, HJ ;
Fihn, SD ;
Rosendaal, FR .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :940-946
[4]   Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation [J].
Hylck, EM ;
Chang, YC ;
Skates, SJ ;
Hughes, RA ;
Singer, DE .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (11) :1612-1617
[5]   Risks factors for highly unstable response to oral anticoagulation: a case-control study [J].
Palareti, G ;
Legnani, C ;
Guazzaloca, G ;
Lelia, V ;
Cosmi, B ;
Lunghi, B ;
Marchetti, G ;
Poli, D ;
Pengo, V .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :72-78
[6]  
PATTACINI C, 1994, THROMB HAEMOSTASIS, V71, P188
[7]   Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation [J].
Penning-van Beest, FJA ;
van Meegen, E ;
Rosendaal, FR ;
Stricker, BHC .
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (02) :569-574